Multiple Sclerosis Market is estimated to be US$ 422.1 Billion by 2034 with a CAGR of 38% during the forecast period

Multiple Sclerosis is considered an autoimmune disease because the immune system, which is designed to protect the body from foreign invaders, mistakenly targets and damages its own myelin, leading to nerve dysfunction. Symptoms of MS can vary widely from person to person and depend on the location and extent of damage within the central nervous system.

Ongoing research and development in the field of MS are likely to yield new and more effective disease-modifying therapies (DMTs) with improved safety profiles. The introduction of these treatments drives multiple sclerosis market growth, as they provide better options for managing the disease. As awareness of MS and its symptoms continues to increase, more individuals may be diagnosed at an earlier stage.Multiple Sclerosis Market was valued at US$ 22.5 Billion in 2024 and is projected to grow at a CAGR of 38% to reach US$ 422.1 Billion by 2034.

The report “Multiple Sclerosis Market, By Type (Primary progressive MS (PPMS), Secondary progressive MS (SPMS), Clinically isolated syndrome (CIS), and Relapse-remitting MS (RRMS)), By Drug Class (Interferons, Immunomodulators, Immunosuppressants, and Others), By Treatment (Physical Therapy, Medications, Plasma Exchange, and Stem Cell Therapy), By End-Users (Specialty Clinics, Homecare, Hospitals, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In May 2023, Sanofi SNY announced positive data from a phase II study, which showed that its novel investigational anti-CD40L antibody, frexalimab, significantly reduced disease activity in patients with relapsing multiple sclerosis. The information was presented at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The primary goal of the trial was attained when it was discovered that after 12 weeks of treatment, greater doses of frexalimab compared to placebo resulted in an 89% decrease in the number of new gadolinium-enhancing (GdE) T1-lesions.

Analyst View:

As more individuals seek and receive therapy, early diagnosis and management may improve results and help the market flourish. Increased illness knowledge, expanding healthcare infrastructure, and improved access to care in emerging nations may result in a larger market share for MS therapies and services in these areas.  

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Multiple Sclerosis Market, By Type (Primary progressive MS (PPMS), Secondary progressive MS (SPMS), Clinically isolated syndrome (CIS), and Relapse-remitting MS (RRMS)), By Drug Class (Interferons, Immunomodulators, Immunosuppressants, and Others), By Treatment (Physical Therapy, Medications, Plasma Exchange, and Stem Cell Therapy), By End-Users (Specialty Clinics, Homecare, Hospitals, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Multiple Sclerosis Market was valued at US$ 22.5 Billion in 2024 and is projected to grow at a CAGR of 38% to reach US$ 422.1 Billion by 2034. Multiple Sclerosis Market is segmented based on Type, Drug Class, Treatment, End-Users and Region.

• Based on Type, Multiple Sclerosis Market is segmented into Primary progressive MS (PPMS), Secondary progressive MS (SPMS), clinically isolated syndrome (CIS), and Relapse-remitting MS (RRMS).
• Based on Drug Class, Multiple Sclerosis Market is segmented into Interferons, Immunomodulators, Immunosuppressants, and Others.
• Based on Treatment, Multiple Sclerosis Market is segmented into Physical Therapy, Medications, Plasma Exchange, and Stem Cell Therapy.
• Based on End-Users, Multiple Sclerosis Market is segmented into Specialty Clinics, Homecare, Hospitals, and Others.
• By Region, the Multiple Sclerosis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Multiple Sclerosis Market:

The prominent players operating in the Multiple Sclerosis Market includes, Pfizer Inc., Bayer AG, AbbVie Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, and Cipla Inc.  

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com